Novavax, a Covid vaccine different from all the ones we have

Despite being close to 90% effective in preventing Covid-19 symptoms, the Novavax vaccine risks staying in the attic for a while longer. In spite of its effectiveness, in fact, the US company – at least as regards the request to the FDA – does not plan to start distributing the product before the autumn. For the rest of the world, approval may even come earlier.